Bank of America
BCRX icon

Bank of America’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bank of America’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.5M Buy
5,091,765
+3,556,208
+232% +$27.6M ﹤0.01% 1615
2025
Q4 		$12M Sell
1,535,557
-367,262
-19% -$2.66M ﹤0.01% 2716
2025
Q3 		$14.4M Sell
1,902,819
-938,336
-33% -$7.81M ﹤0.01% 2926
2025
Q2 		$25.5M Buy
2,841,155
+1,405,498
+98% +$13.1M ﹤0.01% 2315
2025
Q1 		$10.8M Buy
1,435,657
+535,819
+60% +$4.32M ﹤0.01% 3060
2024
Q4 		$6.77M Sell
899,838
-261,127
-22% -$1.98M ﹤0.01% 3300
2024
Q3 		$8.82M Sell
1,160,965
-139,373
-11% -$1.06M ﹤0.01% 3192
2024
Q2 		$8.04M Sell
1,300,338
-65,829
-5% -$363K ﹤0.01% 3168
2024
Q1 		$6.94M Sell
1,366,167
-54,127
-4% -$304K ﹤0.01% 3322
2023
Q4 		$8.51M Buy
1,420,294
+328,776
+30% +$1.91M ﹤0.01% 3060
2023
Q3 		$7.73M Sell
1,091,518
-266,640
-20% -$1.92M ﹤0.01% 2984
2023
Q2 		$9.56M Sell
1,358,158
-2,256,175
-62% -$18.1M ﹤0.01% 2750
2023
Q1 		$30.1M Buy
3,614,333
+2,627,536
+266% +$25.3M ﹤0.01% 1763
2022
Q4 		$11.3M Buy
986,797
+131,916
+15% +$1.65M ﹤0.01% 2569
2022
Q3 		$10.8M Buy
854,881
+92,446
+12% +$1.19M ﹤0.01% 2545
2022
Q2 		$8.07M Buy
762,435
+25,994
+4% +$268K ﹤0.01% 2902
2022
Q1 		$12M Buy
736,441
+379,757
+106% +$6.09M ﹤0.01% 2688
2021
Q4 		$4.94M Sell
356,684
-224,960
-39% -$2.98M ﹤0.01% 3661
2021
Q3 		$8.36M Sell
581,644
-388,484
-40% -$6.13M ﹤0.01% 3040
2021
Q2 		$15.3M Sell
970,128
-379,005
-28% -$5.15M ﹤0.01% 2397
2021
Q1 		$13.7M Buy
1,349,133
+623,274
+86% +$6.43M ﹤0.01% 2396
2020
Q4 		$5.41M Sell
725,859
-133,640
-16% -$689K ﹤0.01% 3060
2020
Q3 		$2.95M Sell
859,499
-932,049
-52% -$3.99M ﹤0.01% 3381
2020
Q2 		$8.54M Buy
1,791,548
+1,129,996
+171% +$4.51M ﹤0.01% 2351
2020
Q1 		$1.32M Buy
661,552
+285,051
+76% +$785K ﹤0.01% 3819
2019
Q4 		$1.3M Buy
376,501
+275,753
+274% +$694K ﹤0.01% 4320
2019
Q3 		$288K Sell
100,748
-321,185
-76% -$999K ﹤0.01% 5438
2019
Q2 		$1.6M Buy
421,933
+180,561
+75% +$1.09M ﹤0.01% 4218
2019
Q1 		$1.97M Buy
241,372
+198,375
+461% +$1.7M ﹤0.01% 4002
2018
Q4 		$347K Buy
42,997
+10,546
+32% +$82K ﹤0.01% 5165
2018
Q3 		$248K Sell
32,451
-83,780
-72% -$563K ﹤0.01% 5362
2018
Q2 		$666K Buy
116,231
+61,960
+114% +$341K ﹤0.01% 4725
2018
Q1 		$259K Sell
54,271
-4,671
-8% -$24K ﹤0.01% 5220
2017
Q4 		$289K Buy
58,942
+32,668
+124% +$158K ﹤0.01% 5240
2017
Q3 		$138K Buy
26,274
+10,240
+64% +$52.4K ﹤0.01% 5546
2017
Q2 		$89K Sell
16,034
-8,995
-36% -$54.8K ﹤0.01% 5645
2017
Q1 		$210K Buy
25,029
+7,568
+43% +$52.6K ﹤0.01% 5287
2016
Q4 		$111K Buy
17,461
+7,810
+81% +$40.6K ﹤0.01% 5574
2016
Q3 		$42K Sell
9,651
-6,294
-39% -$25.1K ﹤0.01% 5791
2016
Q2 		$45K Buy
15,945
+10,445
+190% +$32.4K ﹤0.01% 5866
2016
Q1 		$16K Sell
5,500
-16,985
-76% -$75.3K ﹤0.01% 6220
2015
Q4 		$232K Sell
22,485
-35,107
-61% -$349K ﹤0.01% 5292
2015
Q3 		$657K Sell
57,592
-33,782
-37% -$451K ﹤0.01% 4614
2015
Q2 		$1.36M Buy
91,374
+41,683
+84% +$474K ﹤0.01% 3844
2015
Q1 		$448K Buy
49,691
+823
+2% +$8.52K ﹤0.01% 4396
2014
Q4 		$595K Buy
48,868
+20,569
+73% +$227K ﹤0.01% 4488
2014
Q3 		$277K Sell
28,299
-64,880
-70% -$795K ﹤0.01% 5085
2014
Q2 		$1.19M Buy
93,179
+8,879
+11% +$86.4K ﹤0.01% 3845
2014
Q1 		$892K Sell
84,300
-11,216
-12% -$120K ﹤0.01% 4020
2013
Q4 		$726K Buy
95,516
+11,171
+13% +$70.7K ﹤0.01% 4406
2013
Q3 		$614K Sell
84,345
-96,900
-53% -$492K ﹤0.01% 4438
2013
Q2 		$281K Buy
+181,245
New +$313K ﹤0.01% 5290

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bank of America's BCRX Position: Q1 2026 in Review

Bank of America increased its BioCryst Pharmaceuticals (BCRX) stake by 232% in Q1 2026, buying an estimated $27.6M and bringing the position to 5,091,765 shares worth $48.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Bank of America first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Bank of America held 5,091,765 shares of BioCryst Pharmaceuticals worth $48.5M as of Q1 2026.
  • Bank of America bought 3,556,208 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $27.6M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1615 holding.
  • Bank of America first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.